Evaluation of Effect of Platelet-Rich Fibrin on Orthodontic Tooth Movement: a Split Mouth Randomised Controlled Trial
Dow University of Health Sciences
15 participants
Apr 25, 2024
INTERVENTIONAL
Conditions
Summary
it is a randomized control trial and aims at investigating the effects of PRF on rate of tooth movement and root length to be tested on larger sample size of pakistani population
Eligibility
Inclusion Criteria7
- Patients who give written consent to participate in the research
- Orthodontic patients with good oral hygiene
- Patients with periodontal probing depths≤3 mm with no bone loss
- Patients undergoing orthodontic treatment with fixed appliance and requiring upper first premolar extraction followed by canine retraction
- Patients treated with canine retraction utilizing maximum anchorage in the maxillary arch from trans-palatal arch anchorage device
- Patients with mild to moderate crowding in maxillary arch
- Patients with no previous history of orthodontic treatment
Exclusion Criteria1
- patients who are smokers, health compromised (such as diabetics, with bone disorders, immunocompromised, known with blood dyscrasias) will be excluded from the trial. Patients with drug history of non-steroidal anti-inflammatory drugs, anti-inflammatory (in last 30 days), antibiotic therapy in last 3 months and those women who are pregnant will also be excluded.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06634017